Table 5. Details for each case (n=55).

	Group	Case1			Case 2			Case 3
		N	%		N	%		N	%
Oligometastases?	Agree	49	89		44	80		55	100
	Disagree	6	11		11	20		0	0
Experience treating the case	Yes	44	80		34	62		41	75
	No	11	20		21	38		14	25
RT timing	Upfront RT	48	87		16	29		53	96
	ADT followed by RT	–	–		31	56		–	–
	No RT	7	13		8	15		2	4
RT field	Prostate only	3	6		6	13		0	0
	Prostate and metastatic lesion	20	42		24	51		0	0
	WP and metastatic lesion	25	52		16	34		0	0
	Metastatic lesion only	0	0		1	2		53	100
Fx size for prostate	Conventional fx	9	19		8	17		–	–
	Hypofx	37	77		35	76		–	–
	SBRT	2	4		3	7		–	–
BED for prostate	<88.8 Gy10	36	75		35	76		–	–
	≥88.8 Gy10	12	25		11	24		–	–
Fx size for WP	Conventional fx	22	88		15	94		–	–
	Hypofx	3	12		1	6		–	–
BED for WP	<53.1 Gy10	3	12		1	6		–	–
	≥53.1 Gy10	22	88		15	94		–	–
Fx size for metastatic lesion	Conventional fx	20	45		10a/2b	24/6		1	2
	Hypofx	23	51		21a/11b	52/30		15	28
	SBRT	2	4		10a/23b	24/64		37	70
BED for metastatic lesion	<53.1 Gy10	7	16		9a/19b	22a/53b		36	68
	≥53.1 Gy10	38	84		32a/17b	78a/47b		17	32
Reason for not use SBRTc	WP including regional LNs	22	48		15	39		–
	Preference of other fractionations	18	39		16	42		9	56
	Lack of special equipment	1	2		1	3		0	0
	Lack of experience of SBRT	8	17		9	24		4	25
	Limitation of reimbursement	5	11		15	39		3	19
	Wide margin for involved bone mets	27	59		12	32		5	31
	Others	1	2		0	0		1	6

^a, means pelvic bone metastases; ^b, means T11 spine metastases; ^c, the respondents selected multiple answer. RT, radiotherapy; ADT, androgen deprivation therapy; WP, whole pelvis including regional lymph nodes (LNs); Fx, fraction; Hypofx, hypofractionation; SBRT, stereotactic body radiotherapy; BED, biologically effective dose when α/β was assumed to be 10 Gy.